Strengthening of Ectin Research board of directors
Three new board members joined the company’s board of directors at EGM September 1st, 2020. The reasons behind were to complement the board’s expertise in the upcoming capital raise and planned clinical phase II trial later 2021. The new board members are Carlos de Sousa, Fredrik Sjövall and Fredrik Andersson.
Carlos de Sousa has 30 years of experience ranging from leadership positions at international pharmaceutical and biotech companies. He has achieved several successful capital raises, enabled the advance of early to mid-stage product development and amassed extensive knowledge in creating prosperous licensing agreements and strategic partnerships. He is currently the CEO for Ultimovacs (publ), Oslo, and was previously President and CEO of Immunicum AB.
Fredrik Sjövall has +15y of experience from management positions in the life science industry. He has also listed a number of different life science companies on the stock market. Fredrik is currently the chairman of the board for Ziccum (publ), Lipidor (publ) and Monivent (publ). He was previously the CEO of Hemcheck.
Fredrik Andersson is an investor in Ectin Research with a strong background in pharmaceutical development. He co-founded and sat in the board of another life science company.